Here is the complete information for the combination:
💊 Tenofovir (A) + Lamivudine (B) + Dolutegravir (C)
🧪 Composition:
- Tenofovir disoproxil fumarate (TDF) – 300 mg (equivalent to 245 mg of tenofovir base)
- Lamivudine – 300 mg
- Dolutegravir – 50 mg
Available as a single fixed-dose combination tablet (FDC).
🌐 Therapeutic Class:
- Antiretroviral therapy (ART)
- Used for HIV-1 infection in adults and adolescents
- Combines:
- Tenofovir – Nucleotide Reverse Transcriptase Inhibitor (NtRTI)
- Lamivudine – Nucleoside Reverse Transcriptase Inhibitor (NRTI)
- Dolutegravir – Integrase Strand Transfer Inhibitor (INSTI)
✅ Indications / Uses:
- First-line treatment of HIV-1 infection
- Preferred regimen under National AIDS Control Organisation (NACO) and WHO guidelines
⚖️ Recommended Dosage:
- 1 tablet once daily orally, with or without food
⚠️ Precautions:
- Test for HBV before starting (as withdrawal may cause hepatitis flare in HBV coinfection)
- Monitor renal function (especially due to Tenofovir)
- Not recommended in patients with CrCl < 50 mL/min without adjustment
- Avoid concurrent use of drugs that reduce Dolutegravir levels (e.g., rifampicin – dose adjustment needed)
🚫 Contraindications:
- Known hypersensitivity to any of the components
- Severe renal impairment (CrCl < 30 mL/min, unless adjusted)
- Concurrent use with dofetilide (risk of serious arrhythmia)
💥 Common Side Effects:
- Headache, insomnia, dizziness
- Diarrhea, nausea
- Elevated liver enzymes
- Weight gain (noted with Dolutegravir)
- Rare: lactic acidosis, hepatomegaly
👩⚕️ Use in Special Populations:
- Pregnancy: Generally considered safe; widely used
- Breastfeeding: Caution advised (consult guidelines)
📦 Packaging & Storage:
- Tablets in blister packs or bottles
- Store below 30°C, protect from moisture and light